🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 8 of 151

  1. ALN-6400

    Alnylam Netherlands B.V.

    Von Willebrand Disease (VWD)

    phase 2 small molecule active

    1 trial

  2. ALN-6400

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia

    phase 2 small molecule active

    1 trial

  3. ALN-AAT02

    Alnylam Netherlands B.V.

    ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

    phase 2 small molecule terminated

    1 trial

  4. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  5. ALN-ANG3

    Regeneron UK Limited

    Diabetic Kidney Disease (DKD)

    phase 2 small molecule active

    1 trial

  6. ALN-CC5

    Alnylam Netherlands B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  7. ALN-CFB

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  8. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  9. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  10. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  11. ALN-PNP

    Regeneron UK Limited

    Healthy Volunteers

    phase 2 small molecule active

    1 trial

  12. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  13. ALN-RSV01

    Alnylam Netherlands B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    3 trials

  14. ALN-SOD

    Regeneron UK Limited

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  15. ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  16. ALN-TTRSC (revusiran) for subcutaneous administration

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  17. ALN-XDH

    Alnylam Netherlands B.V.

    Gout

    phase 2 small molecule terminated

    1 trial

  18. ALPELISIB, FULVESTRANT, ALPELISIB, LETROZOLE, LEUPRORELIN ACETATE, GOSERELIN

    Novartis Pharmaceuticals

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  19. ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011

    Novartis Pharmaceuticals

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  20. ALPN-101

    Vertex Pharmaceuticals (Australia) Pty.

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  21. ALX-0061

    Sanofi Pasteur

    Lupus Erythematosus, Systemic

    phase 2 mab completed

    1 trial

  22. ALX-0600

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  23. ALX1-11 50 mcg

    Takeda

    Osteoporosis

    phase 2 small molecule completed

    1 trial

  24. ALXN 2040, Placebo matching ALXN2040

    Alexion Europe SAS

    Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    phase 2 small molecule active

    1 trial

  25. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  26. ALXN2420, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, matching placebo for ALXN2420, LANREOTIDE ACETATE, OCTREOTIDE ACETATE

    Alexion Europe SAS

    Acromegaly

    phase 2 small molecule active

    1 trial

  27. AMBROXOL , Microcrystalline cellulose

    Disc Medicine

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  28. AMG 133, Placebo for AMG 133

    Amgen

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  29. AMG 193

    Amgen

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. AMG 193, AMG 193, AMG 193

    Amgen

    Advanced MTAP-null solid tumors

    phase 2 small molecule active

    1 trial

  31. AMG 193, IDE397, AMG 193, IDE397, AMG 193

    Amgen

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. AMG 706

    Takeda

    Advanced Gastrointestinal Stromal Tumor

    phase 2 small molecule completed

    1 trial

  33. AMG 732

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  34. AMG531

    KYOWA KIRIN AUSTRALIA PTY LTD

    Aplastic Anemia

    phase 2 small molecule completed

    1 trial

  35. AMGLIDIA 6 mg/mL oral suspension

    Pari Pharma GmbH

    Transient hyperglycaemia in premature infants

    phase 2 small molecule active

    1 trial

  36. AMINOHIPPURIC ACID, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Felzartamab

    Istituto Gentili S.r.l.

    Membranous nephropathy

    phase 2 small molecule active

    1 trial

  37. AMO959, ENZALUTAMIDE, Enzalutamide, Prednison 5 mg GALEN® Tabletten, -, DEGARELIX, RELUGOLIX, Prednison acis 5 mg, Pluvicto 1 000 MBq/mL solution for injection/infusion, ABIRATERONE, Abiraterone, PIFLUFOLASTAT (18F), AMO959, GOZETOTIDE, DEGARELIX

    Novartis Pharmaceuticals

    PSMA-positive mCRPC with prior exposure to at least one prior ARPI

    phase 2 small molecule active

    1 trial

  38. AMPHOTERICIN B , VANCOMYCIN , Gentamicin_APHP

    Pari Pharma GmbH

    Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission

    phase 2 small molecule active

    1 trial

  39. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    ALS

    phase 2 small molecule active

    1 trial

  40. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  41. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Wolfram Syndrome

    phase 2 small molecule active

    1 trial

  42. AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY IN PARTICIPANTS TREATED WITH CRN04894

    Lacuna Pharma Pty Ltd

    CONGENITAL ADRENAL HYPERPLASIA

    phase 2 other active

    1 trial

  43. AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT)

    Minoryx Therapeutics S.L.

    CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD)

    phase 2 other active

    1 trial

  44. ANAKINRA

    Disc Medicine

    Intracerebral haemorrhage

    phase 2 small molecule active

    1 trial

  45. ANAKINRA

    AXIM BIOTECHNOLOGIES, INC.

    Hyperinflammation, Sepsis

    phase 2 small molecule active

    1 trial

  46. ANEB-001

    Anebulo Pharmaceuticals

    Acute Cannabinoid Intoxication

    phase 2 small molecule completed

    1 trial

  47. AP-PA02

    Armata Pharmaceuticals

    Non-cystic Fibrosis Bronchiectasis

    phase 2 mab completed

    1 trial

  48. AP-PA02

    Armata Pharmaceuticals

    Cystic Fibrosis

    phase 2 mab completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.